March 26, 2014
Novartis Pharma said on March 25 that Rasilamlo, a fixed-dose combination drug of aliskiren and amlodipine approved the previous day for hypertension, will not be put on sale in the Japanese market amid sluggish demand overseas. Although “certain medical needs...read more